

## Video Article

# Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Hilary C. Rees<sup>1</sup>, Voichita Ianas<sup>1</sup>, Patricia McCracken<sup>1</sup>, Shannon Smith<sup>1</sup>, Anca Georgescu<sup>1</sup>, Tirdad Zangeneh<sup>1</sup>, Jane Mohler<sup>2</sup>, Stephen A. Klotz<sup>1</sup>

<sup>1</sup>Division of Infectious Diseases, University of Arizona

<sup>2</sup>Arizona Center on Aging, University of Arizona

Correspondence to: Stephen A. Klotz at [sklotz@u.arizona.edu](mailto:sklotz@u.arizona.edu)

URL: <http://www.jove.com/video/50537>

DOI: [doi:10.3791/50537](https://doi.org/10.3791/50537)

Keywords: Medicine, Issue 77, Infection, Virology, Infectious Diseases, Anatomy, Physiology, Molecular Biology, Biomedical Engineering, Retroviridae Infections, Body Weight Changes, Diagnostic Techniques and Procedures, Physical Examination, Muscle Strength, Behavior, Virus Diseases, Pathological Conditions, Signs and Symptoms, Diagnosis, Musculoskeletal and Neural Physiological Phenomena, HIV, HIV-1, AIDS, Frailty, Depression, Weight Loss, Weakness, Slowness, Exhaustion, Aging, clinical techniques

Date Published: 7/24/2013

Citation: Rees, H.C., Ianas, V., McCracken, P., Smith, S., Georgescu, A., Zangeneh, T., Mohler, J., Klotz, S.A. Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty. *J. Vis. Exp.* (77), e50537, doi:10.3791/50537 (2013).

## Abstract

A simple, validated protocol consisting of a battery of tests is available to identify elderly patients with frailty syndrome. This syndrome of decreased reserve and resistance to stressors increases in incidence with increasing age. In the elderly, frailty may pursue a step-wise loss of function from non-frail to pre-frail to frail. We studied frailty in HIV-infected patients and found that ~20% are frail using the Fried phenotype using stringent criteria developed for the elderly<sup>1,2</sup>. In HIV infection the syndrome occurs at a younger age.

HIV patients were checked for 1) unintentional weight loss; 2) slowness as determined by walking speed; 3) weakness as measured by a grip dynamometer; 4) exhaustion by responses to a depression scale; and 5) low physical activity was determined by assessing kilocalories expended in a week's time. Pre-frailty was present with any two of five criteria and frailty was present if any three of the five criteria were abnormal.

The tests take approximately 10-15 min to complete and they can be performed by medical assistants during routine clinic visits. Test results are scored by referring to standard tables. Understanding which of the five components contribute to frailty in an individual patient can allow the clinician to address relevant underlying problems, many of which are not evident in routine HIV clinic visits.

## Video Link

The video component of this article can be found at <http://www.jove.com/video/50537/>

## Introduction

The Centers for Disease Control projects that more than half of HIV-1 infected individuals in the United States will be over the age 50 by the year 2015. The increasing life expectancy of HIV-1 infected patients has resulted in an unexpected increase in aging-related co-morbidities, placing HIV-positive elders at increased risk of morbidity and mortality. One important example of this is with the newly described syndrome of frailty, which may play an important role in accelerated aging of HIV-1 infected adults.<sup>3-7</sup>

Frailty has been defined in the aged as a biologic syndrome of decreased reserve and resistance to stressors, resulting from the cumulative decline of physiologic systems and often progresses in a step-wise functional decline over time. The clinical importance of frailty is that the syndrome is considered a high-risk state, predictive of adverse health outcomes such as decreased function and mobility, hospitalization and death.<sup>8</sup> Numerous studies in the last 10 years have tried to assess frailty in different populations. Fried *et al.* studied frailty in men and women older than 65 years of age who were enrolled in a cardiovascular study.<sup>2</sup> Their definition of frailty was validated in a study of aging women.<sup>9</sup> Modifications of their definition have been used in other studies including HIV-1 infected individuals.<sup>4-7</sup> Fried *et al.* described a frail phenotype that even in the absence of disabilities or co-morbidities showed that 7% of population older than 65 years of age are frail whereas, 20-26% older than 80 years of age were frail.<sup>2</sup> Frailty can be a primary finding,<sup>10</sup> but also a secondary diagnosis as a result of an acute event or co-morbidity like malignancy, atherosclerosis, infection (HIV), or depression.<sup>10</sup> Additionally, other factors likely contribute to frailty in HIV patients, for example, intravenous drug abuse, indigence and mental illness.

Frailty has been found in HIV-1 infected patients at younger ages than non-HIV infected patients.<sup>4</sup> Older HIV-1 infected individuals frequently present with more severe HIV disease and have a shorter survival time than younger individuals, often because they are not diagnosed until very late in the disease process.<sup>11</sup> Another reason may be that older patients have more co-morbid diseases interacting with HIV-1. Older HIV-1 infected individuals have been described as frailer than age-matched control individuals without HIV-1 infection.<sup>4</sup>

Clinical measurement of frailty in HIV-1 infected patients is important as frailty may be reversible in its early stages (e.g. interventions to reverse deconditioning, protein-energy malnutrition, depression, vitamin D deficiency and other frailty related conditions) before depleted reserves reach a critical threshold leading to irreversible vulnerability and functional decline.

## Protocol

Because it is impractical to test for frailty in all patients attending an HIV clinic we recommend the following patients be assessed for the presence of frailty: patients entering care with a CD4 cell count <200, patients complaining of unintentional weight loss, severe neuropathy or patients who are not compliant with HIV therapy.

1. Obtain verbal consent of the patient to undergo tests for frailty or "weakness". Consent need not be written since everything that is performed is part of a normal physical examination.
2. Perform a Mini-Cog test if the patient appears confused or apathetic.
  1. Instruct the patient to listen carefully to, and remember 3 unrelated words. The examiner states the three words out loud.
  2. Instruct the patient to draw the face of a clock, either on a blank sheet of paper or on a sheet with the clock circle already drawn on the page. After the patient puts the numbers on the clock face, ask him or her to draw the hands of the clock to read a specific time.
  3. Ask the patient to repeat the 3 previously stated words. Give 1 point for each recalled word. Patients recalling none of the three words are classified as cognitively impaired (Score = 0). Patients recalling all three words are classified as cognitively intact (Score = 3) Patients with intermediate word recall of 1-2 words are classified based on the clock draw test (Abnormal = impaired; Normal = intact).
  4. If the patient fails the Mini-Cog, the clinician should examine further for causes of confusion and/or delirium. Testing for frailty would not be appropriate at this time.
3. Weigh patient and assess for weight loss. Someone who is frail may have unintentional weight loss of  $\geq 10$  pounds in the prior year.
4. Time a patient's walk for slowness. Someone who is frail has a decreased walking time as defined by a timed 15-foot walk test. The time is adjusted for gender and standing height. Men with a height of <173 cm and women with a height <159 cm who walked 15 feet in >7 sec are considered frail; men >173 cm and women >159 cm who walked 15 feet in >6 sec are considered frail.
5. Determine if the patient has weakness. Weakness is established when there is decreased grip strength measured by a dynamometer with the value adjusted for gender and body mass index (BMI). Men with a BMI <24 are considered frail if the grip strength (kg) is <29, for a BMI of 24.1-28, a man is frail if <30, for a BMI >28 a man is frail if <32. For women, a BMI of <23 is considered frail if the grip strength (kg) is <17, a BMI 23.1-26 is considered frail if <17.3, a BMI of 26.1-29 is considered frail if <18, and a BMI >29 is considered frail if <21.
6. Determine if the patient has a low physical activity level. This is established by a weighted score of kilocalories expended per week measured by the Minnesota Leisure Time Activity Questionnaire. The questionnaire asks about activities like daily living, sports and hobbies. Frailty is present when males use <383kcal/week, and females <270 kcal/week.<sup>12</sup>
7. Determine if the patient shows evidence of exhaustion. This is self-reported by answering 2 questions from the Center for Epidemiologic Studies Depression Scale.<sup>13</sup> The questions asked are: How often in the last week did you feel: (a) that everything I did was an effort?; or (b) I could not get going? Answers were: 0 = less than 1 day, 1 = 1-2 days, 2 = 3-4 days, 3 = most of the time. Answering 2 or 3 to either of these questions is a positive criterion for frailty.<sup>14</sup>

## Representative Results

One hundred outpatient HIV-1-infected persons were prospectively tested for clinical markers of frailty to include shrinking weight, slowness in walking, decrease in grip strength, low activity, and exhaustion. Eighty-one patients were not frail when studied, 19 patients were frail at the initial assessment (**Table 1**). The characteristics of the frail and non-frail patients were not significantly different except for a higher rate of hepatitis C and neuropathy in the frail group ( $p < 0.05$ ). Length of infection with HIV, CD4 count and HIV-1 RNA viral load were also compared. As shown in **Table 2** the younger patients had a greater incidence of frailty and this was associated with low CD4 cell counts. CD4 counts <200 cells/mm<sup>3</sup> were associated with 9-fold increased odds of frailty relative to patients with a CD4 count >350 cells/mm<sup>3</sup> (odds ratio [OR] 9.0, 95% confidence interval [CI] 2.1-44). Seven frail patients were measured 6 months later: 2 died refusing therapy, 4 were no longer frail, and 1 patient remained frail (**Table 3**). From this data it appears that when patients took prescribed anti-retroviral therapy the CD4 cell counts improved along with an improvement in the general state of health of the patient. Finally, if the incidence of frailty in the study population is compared to the number of years of anti-retroviral therapy taken by the patients, the longer patients took anti-retroviral therapy, the less the incidence of frailty ( $p < 0.05$ ). This fact supports the early use of anti-retroviral therapy in HIV-infected patients which is the preferred approach in recent HIV treatment guidelines.<sup>15</sup>

We conclude that frailty is common in HIV outpatients and is associated with low CD4 counts more than with advancing age. Our data suggest that frailty is transient, especially in younger patients who may revert to their prefrail state unlike uninfected elderly individuals in whom a stepwise decline in function may occur.

### Representative Results from our Previous Study<sup>1</sup>

		Frail, N=19 (19%)	Non-Frail, N=81 (81%)
<b>Sex</b>	Male	14 (74%)	60 (74%)
	Female	5 (26%)	21 (26%)
<b>Age</b>	<50	12 (63%)	46 (57%)
	$\geq 50$	7 (37%)	35 (43%)
<b>Comorbidity</b>	Dyslipidemia	6 (32%)	25 (31%)

	Psychiatric	4 (21%)	29 (36%)
	Neuropathy	8 (42%)	15 (19%)
	Hypertension	2 (11%)	17 (21%)
	Hepatitis C	6 (32%)	12 (15%)
	Diabetes mellitus	3 (16%)	6 (7%)
	Coronary artery disease	1 (1%)	5 (6%)


**Table 1. Clinical characteristics of the HIV study patients.** Frail patients were compared to non-frail HIV patients with respect to sex, age and comorbidities. The presence of neuropathy and infection with hepatitis C were significant differences between the frail and non-frail patients.

CD4 Cell Count (cells/ $\mu$ l)	<50 Years of Age, N (%)	$\geq$ 50 Years of Age, N (%)
<200	7	3
200-350	4	1
>350	1	3
P-value	0.028	0.021

**Table 2. Frail patients and the relationship of age and CD4 cell count in these patients.** The frail patients were significantly younger and with lower CD4 cell counts than non-frail patients.

Patient	Initial CD4 Cell Count (cells/ $\mu$ l)	Initial Viral Load (RNA copies/ $\mu$ l)	Retest CD4 Cell Count (cells/ $\mu$ l)	Retest Viral Load (RNA copies/ $\mu$ l)	Comorbidity	Outcome
1	26	2 million	N/A	N/A	hepatitis C, alcoholism	Dead; refused ART
2	3	52,000	1	82,000	coccidioidomycosis	Dead; stopped ART
3	12	12,000	36	<48	none	Not frail
4	169	<48	991	<48	blindness, peripheral neuropathy, pulmonary embolism	Not frail
5	141	1,000	54	<48	lymphoma, peripheral neuropathy	Not frail
6	151	<48	393	<48	coccidioidomycosis, deep venous thrombosis	Not frail
7	106	44,620	229	<48	hepatitis C, chronic obstructive lung disease	Frail

**Table 3. Outcomes of 7 frail patients with low CD4 cell counts.** These patients all needed anti-retroviral therapy, were prescribed therapy and then retested for frailty 6 months later. Only one patient who took the prescribed anti-retroviral therapy was still frail 6 months later.



**Figure 1. Relationship between number of years of taking anti-retroviral therapy and the incidence of frailty (89 patients were taking anti-retroviral therapy).** The longer patients took anti-retroviral therapy the less the incidence of frailty in that population ( $p < 0.05$ ).

## Discussion

**Previous studies of HIV and frailty:** Two retrospective studies by Desquilbet *et al.* assessed frailty in a cohort of men who have sex with men from the Multicenter AIDS Cohort Studies (MACS). Both studies used a shortened definition of frailty containing fewer criteria than did our study. The first study compared frailty in HIV-1 infected men in the pre-treatment era to a control group of HIV uninfected men.<sup>4</sup> There were similar rates of frailty in HIV+ men older than 55 years and HIV- men older than 65 years; frailty was found to occur earlier in HIV-1 infected men. Our study had similar findings of an earlier occurrence of frailty phenotype, but we obtained higher rates of frailty compared with MACS, possibly because our use of the full Fried frailty criteria versus surrogate administrative data, but also because of the different population of patients in our study.

Another study by Desquilbet *et al.* evaluated CD4 cell count and HIV viral load as predictors of frailty in HIV+ men and found that lower CD4 cell counts and viral loads of more than 50,000 copies of RNA were significantly associated with frailty.<sup>5</sup> Also the prevalence of frailty declined in the era of ART. Despite differences in measuring frailty and in population characteristics our study concluded like Desquilbet *et al.* that a low CD4 cell count is significantly associated with frailty and that patients on long-term ART have less likelihood of developing frailty.<sup>1</sup> Premature occurrence of prevalence of frailty, shorter duration of ART, more co-morbidities and lower CD4 count were associated with frailty in both studies, but we did not find a strong association between psychiatric diagnosis and frailty. We found a positive relationship between length of ART and not being frail (**Figure 1**).

**Our findings of frailty in HIV patients:** Our initial hypothesis that age was not significantly important when measuring frailty of patients with low CD4 cell counts was confirmed. Frailty is likely more causally related to the inflammatory state and profound immunosuppression found in many patients with low CD4 cell counts. Many of these patients had a history of recently treated opportunistic infections. Because of these observations we propose that an active diagnosis of AIDS (CD4 cell count  $<200$  cells/ $\mu$ l) is a significant co-morbidity itself and significantly predisposes patients to being frail. All of our frail patients had at least one co-morbidity besides HIV itself. Our frail patients  $<50$  years had significantly fewer co-morbidities than the frail population  $>50$  years, though in comparison, the younger people had a lower CD4 cell count.

Our other hypothesis was that frailty may be temporary in younger patients with low CD4 cell counts and may revert when CD4 cell counts improve. We were limited by the low number of patients and this hypothesis could not be proven, but it was a likely explanation for the small number of patients in which reversal was demonstrated (**Table 1**). Longer antiretroviral treatment was found to be protective for frailty (**Figure 1**). This fact on its own would support the recommendations of starting ART at higher CD4 counts and continuing ART without any treatment breaks. We believe that the main reason by which length of ART treatment was shown to be protective for frailty is that patients on long term treatment are more likely to have better control of co-morbidities as well as HIV and less likely to be frail.

In conclusion we have observed an association between low CD4-cell counts and frailty, which is not affected by age, viral load or the presence of co-morbidities. Effective treatment with ART plays a protective role against frailty, reinforcing the importance of effective ART. Early implementation of ART in the care of HIV patients may protect against frailty. Though not tested in our study, future research should address other interventions known to reverse frailty in the aged including treating deconditioning, protein-energy malnutrition, depression, and vitamin D deficiency.

## Disclosures

No conflicts of interest declared.

## References

1. Ianas, V., Berg, E., Mohler, M.J., Wendel, C., & Klotz, S.A. Antiretroviral therapy protects against frailty in HIV-1 infection. *J. Int. Assoc. Physicians AIDS Care.*, (2012).
2. Fried, L.P., Tangen, C.M., *et al.* Frailty in older adults: evidence for a phenotype. *J. Gerontol. A. Biol. Sci. Med. Sci.* **56** (3), M146-56 (2001).
3. Effros, R.B., Fletcher, C.V., *et al.* Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. *Clin. Infect. Dis.* **47** (4), 542-553 (2008).
4. Desquilbet, L., Jacobson, L.P., *et al.* HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. *J. Gerontol. A. Biol. Sci. Med. Sci.* **62** (11), 1279-1286 (2007).
5. Desquilbet, L., Margolick, J.B., *et al.* Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. *J. Acquir. Immune Defic. Syndr.* **50** (3), 299-306 (2009).
6. Onen, N.F., Agbebi, A., *et al.* Frailty among HIV-infected persons in an urban outpatient care setting. *J. Infect.* **59** (5), 346-352 (2009).
7. Terzian, A.S., Holman, S., *et al.* Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. *J. Womens Health (Larchmt).* **18** (12), 1965-1974 (2009).
8. Ahmed, N., Mandel, R., & Fain, M.J. Frailty: an emerging geriatric syndrome. *Am. J. Med.* **120** (9), 748-753 (2007).
9. Bergman, H., Ferrucci, L., *et al.* Frailty: an emerging research and clinical paradigm--issues and controversies. *J. Gerontol. A. Biol. Sci. Med. Sci.* **62** (7), 731-737 (2007).
10. Bandeen-Roche, K., Xue, Q.L., *et al.* Phenotype of frailty: characterization in the women's health and aging studies. *J. Gerontol. A. Biol. Sci. Med. Sci.* **61** (3), 262-266 (2006).
11. Wilson, J.F. Frailty--and its dangerous effects--might be preventable. *Ann. Intern. Med.* **141** (6), 489-492 (2004).
12. Martin, C.P., Fain, M.J., & Klotz, S.A. The older HIV-positive adult: a critical review of the medical literature. *Am. J. Med.* **121** (12), 1032-1037 (2008).
13. Taylor, H.L., Jacobs, D.R., *et al.* A questionnaire for the assessment of leisure time physical activities. *J. Chronic Dis.* **31** (12), 741-755 (1978).
14. Radloff, L. The CES-D Scale: A self-report depression scale for research in the general population. *Applied Psychological Measurement.* **1** (3), 385-401 (1977).
15. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Accessed 1/5/13 at: <http://aidsinfo.nih.gov>, (2013).